Provided by Tiger Fintech (Singapore) Pte. Ltd.

Aberdeen Income Credit Strategies Fund

5.93
+0.03000.51%
Post-market: 5.930.00000.00%16:04 EDT
Volume:587.84K
Turnover:3.48M
Market Cap:98.26M
PE:9.81
High:5.93
Open:5.91
Low:5.89
Close:5.90
Loading ...

Acadia Pharmaceuticals, Saniona announce results from ACP-711 cohorts

TIPRANKS
·
03 Mar

Acadia Pharmaceuticals and Saniona Announce Initial Positive Results from ACP-711 (formerly SAN711) Phase 1 Study

Business Wire
·
03 Mar

EchoStar Announces Financial Results for the Three and Twelve Months Ended December 31, 2024

PR Newswire
·
27 Feb

abrdn Emerging Markets Ex-China Fund, Inc. (AEF) Announces Final Results of Cash Tender Offer

ACCESS Newswire
·
26 Feb

Charter Communications, Inc. (CHTR): Among the Best Forever Stocks to Buy Right Now

Insider Monkey
·
16 Feb

Here’s Brennan Asset Management’s Updates on Charter (CHTR)

Insider Monkey
·
13 Feb

U.S. FDA Approves Expanded Label for Astellas' IZERVAY™ (avacincaptad pegol intravitreal solution) for Geographic Atrophy

PR Newswire
·
13 Feb

abrdn U.S. Closed-End Funds Announce Distribution Payment Details

ACCESS Newswire
·
12 Feb

Is It Time to Buy AT&T Ahead of a Big Buyback?

Motley Fool
·
07 Feb

Astellas Submits New Drug Application for Conditional Approval of Avacincaptad Pegol for Geographic Atrophy in Japan

PR Newswire
·
05 Feb

abrdn U.S. Closed-End Funds Announce Distribution Payment Details

ACCESS Newswire
·
01 Feb

Sequans Acquires Zurich-based ACP

Newsfile
·
21 Jan

abrdn Asia-Pacific Income Fund VCC Announces Details on 2025 Redemption and Proposal to Eliminate 10% Cap on Annual Redemptions

ACCESSWIRE
·
16 Jan

abrdn U.S. Closed-End Funds Announce Distribution Payment Details

ACCESSWIRE
·
11 Jan

U.S. FDA Confirms Class 1 Resubmission of the Supplemental New Drug Application for IZERVAY™ (avacincaptad pegol intravitreal solution) for Geographic Atrophy

PR Newswire
·
09 Jan